Somite AI, a next-gen TechBio company, has raised over $47 million in Series A funding to reinvent how human cells are created for therapy. The round was led by Khosla Ventures, with strong support from SciFi VC, the Chan Zuckerberg Initiative, Fusion Fund, and others. Notable angel investors include Dr. R. Martin Chavez and Fidji Simo, who recently transitioned from Instacart to OpenAI.
This investment gives Somite AI the firepower to accelerate development across key areas—diabetes, orthopedic care, muscular diseases, and blood disorders. At the core of this effort is DeltaStem, the company’s flagship AI-powered foundation model for human cell creation.
DeltaStem: A Foundation Model Built for Cell Therapy Breakthroughs
DeltaStem isn’t just another bioinformatics tool—it’s a foundational leap. The platform is designed to simulate and guide the production of human cells with unmatched speed and accuracy. Somite’s proprietary capsule technology feeds the model with massive amounts of cell state transition data, operating at 1000x the efficiency of traditional methods.
This gives DeltaStem the unique ability to develop cell differentiation protocols that are not only precise but also scalable. The goal? To make cell therapy faster, cheaper, and far more reliable.
“We’re building the foundation model for the human cell,” said Dr. Micha Breakstone, founder and CEO. “Our model can generate protocols that deliver unmatched purity, consistency, and scalability. Think of this as an AlphaFold moment for developmental biology—only this time, it’s for every cell type.”
A Vision to Democratize Regenerative Medicine
Somite’s mission goes beyond speeding up R&D. By combining AI foundation models with advanced biology, the team wants to make any human cell available to anyone—without the cost and delays that plague traditional cell therapy.
Vinod Khosla, whose firm led the round, sees massive potential. “Traditional cell therapies are expensive and unpredictable. Somite’s models offer a systematic solution,” he said. “This isn’t just about their pipeline—it’s about transforming the entire field.”
With this fresh funding, Somite AI is poised to scale its DeltaStem platform and move multiple therapeutic programs closer to clinical reality. The startup is now one step closer to unlocking truly programmable cell manufacturing—a future where cell therapies are accessible, fast, and personalized.
